3 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 177 | 2021-05-26 | 2025-10-02 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) parsaclisib, ruxolitinib, placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Terminated | Incyte Corporation | 252 | 2021-05-24 | 2025-10-21 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
Myeloproliferative Disorders (3) · Primary Myelofibrosis (3)
Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3)
parsaclisib (2) · ruxolitinib (2) · fedratinib (1)
Incyte Corporation (2) · Celgene (1)
United States (3) · Austria (2) · Belgium (2) · China (2) · Finland (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Norway (2) · Poland (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2)
Albert Assad, M.D (1) · Albert Assad, M.D. (1)
2018 (1)